Title

Effects of atorvastatin on dyslipidemia in uraemic patients on peritoneal dialysis .

Purpose

To evaluate the efficacy and safety of atorvastatin, a potent cholesterol- and triglyceride-lowering agent, in peritoneal dialysis patients with dyslipidemia .

Patients

31 peritoneal dialysis patients with hypercholesterolemia (mean age 57 ± 16 years; mean duration of peritoneal dialysis
27 ± 17 months).

Follow-up

4 months

Treatment regimen

Atorvastatin 10-40 mg/day

Results

• Mean LDL cholesterol levels decreased significantly by 42% and 46% from 204 ± 23 mg/dl to 119 ± 27 mg/dl and
198 ± 37 to 104 ± 21 mg/dl in the primary and secondary prevention patients respectively.
• Mean triglyceride levels decreased by 37% and 26% from 289 ± 132 mg/dl to 186 ± 92 mg/dl and 201 ± 62 to 150 ± 54
mg/dl in the primary and secondary prevention patients respectively.
• Nineteen primary prevention and seven secondary prevention patients achieved the LDL cholesterol target. The
triglyceride target was achieved by 15 of the 19 hypertriglyceridemic patients.
• After 4 months, there were no changes in enzyme levels .

Conclusion

Atorvastatin is an effective and safe lipid-lowering agent for peritoneal dialysis patients with mixed dyslipidemia.